ArticleThe American journal of psychiatry2022
Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
Article in The American journal of psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- A systematic review of remotely delivered contingency management treatment for substance use.Journal of substance use and addiction treatment · 2023Pooled it
- A Framework for Emergency Department-Integrated Hepatitis C Test-and-Treat in the United States.Journal of viral hepatitis · 2026Review
- Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities.Nursing open · 2026Review
- Buprenorphine Dispensation After X-Waiver Elimination by Clinician Specialty.American journal of preventive medicine · 2025Article
- Analysis of buprenorphine distribution patterns among pharmacies and hospitals in the USA from 2019 to 2023.BMJ open · 2025Article
- Emergency Department Visits, Inpatient Hospitalizations, and Nonfatal and Fatal Drug Overdoses During COVID-19 Among Veterans With Opioid Use Disorder.Journal of studies on alcohol and drugs · 2025Article
- Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic : State Telehealth Policies and Buprenorphine.Journal of general internal medicine · 2025Article
- Overcoming barriers to traditional care delivery and pharmacy challenges: a qualitative study of buprenorphine, telehealth, and a digital therapeutic for opioid use disorder.Substance abuse treatment, prevention, and policy · 2025Article
- Telehealth and disparities in opioid use disorder treatment: Medicaid enrollees versus privately insured individuals.Health services research · 2025Article
- Equal Access, Equal Outcomes: Telehealth Utilization Around the COVID-19 Pandemic among People Living with HIV and Opioid Use Disorder in the Deep South.AIDS and behavior · 2025Article
- Patient Engagement in Providing Telehealth SUD IOP Treatment: A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2024Article
- Patients' and Clinicians' Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study.Journal of general internal medicine · 2024Article
- Telehealth Utilization for Opioid Use Disorder: A Nationwide Analysis Before and After the COVID-19 Public Health Emergency Declaration.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2024Article
- Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment.Health affairs scholar · 2024Article
- Prescriptions for Buprenorphine in Michigan Following an Education Intervention.JAMA network open · 2023Article
- Impact of COVID-19 on stimulant use disorder treatment: A national cohort study in the Veterans Health Administration.Drug and alcohol dependence · 2023Article
- Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.JAMA network open · 2023Article
- Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder.JAMA health forum · 2023Observational
- Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians.Journal of general internal medicine · 2023Article
- Overall and Telehealth Addiction Treatment Utilization by Age, Race, Ethnicity, and Socioeconomic Status in California After COVID-19 Policy Changes.JAMA health forum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe authors examined the impact of COVID-19-related policies reducing barriers to telehealth delivery of buprenorphine treatment for opioid use disorder (OUD) on buprenorphine treatment across different modalities (telephone, video, and in-person visits).
methodsThis was a national retrospective cohort study with interrupted time-series analyses to examine the impact of policy changes in March 2020 on buprenorphine treatment for OUD in the Veterans Health Administration, during the year before the start of the COVID-19 pandemic (March 2019 to February 2020) and during the first year of the pandemic (March 2020 to February 2021). The authors also examined trends in the use of telephone, video, and in-person visits for buprenorphine treatment and compared patient demographic characteristics and retention in buprenorphine treatment across the two periods.
resultsThe number of patients receiving buprenorphine increased from 13,415 in March 2019 to 15,339 in February 2021. By February 2021, telephone visits were used by the most patients (50.2%; 4,456 visits), followed by video visits (32.4%; 2,870 visits) and in-person visits (17.4%; 1,544 visits). During the pre-pandemic period, the number of patients receiving buprenorphine increased significantly by 103 patients per month. After the COVID-19 policy changes, there was an immediate increase of 265 patients in the first month, and the number continued to increase significantly, at a rate of 47 patients per month. The demographic characteristics of patients receiving buprenorphine during the pandemic period were similar to those during the pre-pandemic period, but the proportion of patients reaching 90-day retention on buprenorphine treatment decreased significantly from 49.6% to 47.7%, while days on buprenorphine increased significantly from 203.8 to 208.7.
conclusionsThe number of patients receiving buprenorphine continued to increase after the COVID-19 policy changes, but the delivery of care shifted to telehealth visits, suggesting that any reversal of COVID-19 policies must be carefully considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.